REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights
REGENXBIO Inc. (Nasdaq: RGNX) has announced a conference call scheduled for Thursday, August 1, 2024, at 4:30 p.m. ET. The purpose of this call is to discuss the company's financial results for the second quarter ended June 30, 2024, along with recent operational highlights. Interested parties can access the live call by phone or via webcast on the REGENXBIO website. For phone access, dial (646) 307-1963 (domestic) or (800) 715-9871 (international) with passcode 4849384. The recorded webcast will be available for approximately 30 days after the call. Participants are advised to join 15 minutes before the start time.
REGENXBIO Inc. (Nasdaq: RGNX) ha annunciato una conferenza telefonica programmata per giovedì 1 agosto 2024, alle 16:30 ET. Lo scopo di questa chiamata è discutere i risultati finanziari del secondo trimestre chiuso il 30 giugno 2024, insieme ai recenti eventi operativi salienti. Le parti interessate possono accedere alla chiamata dal vivo per telefono o tramite webcast sul sito web di REGENXBIO. Per l'accesso telefonico, comporre il numero (646) 307-1963 (nazionale) o (800) 715-9871 (internazionale) con il codice di accesso 4849384. La registrazione del webcast sarà disponibile per circa 30 giorni dopo la chiamata. Si consiglia ai partecipanti di unirsi 15 minuti prima dell'orario di inizio.
REGENXBIO Inc. (Nasdaq: RGNX) ha anunciado una conferencia telefónica programada para el jueves 1 de agosto de 2024, a las 4:30 p.m. ET. El propósito de esta llamada es discutir los resultados financieros del segundo trimestre finalizado el 30 de junio de 2024, junto con los recientes aspectos operativos destacados. Las partes interesadas pueden acceder a la llamada en vivo por teléfono o a través de webcast en el sitio web de REGENXBIO. Para el acceso telefónico, marque el (646) 307-1963 (nacional) o el (800) 715-9871 (internacional) con el código de acceso 4849384. La grabación del webcast estará disponible durante aproximadamente 30 días después de la llamada. Se aconseja a los participantes unirse 15 minutos antes de la hora de inicio.
REGENXBIO Inc. (Nasdaq: RGNX)는 2024년 8월 1일 목요일 오후 4:30 ET에 예정된 전화 회의를 발표했습니다. 이 통화의 목적은 2024년 6월 30일에 종료된 두 번째 분기의 재무 결과와 최근 운영 하이라이트를 논의하는 것입니다. 관심 있는 분들은 REGENXBIO 웹사이트에서 전화 또는 웹캐스트를 통해 생중계에 접속할 수 있습니다. 전화로 접속할 경우 (646) 307-1963(국내) 또는 (800) 715-9871(국제)로 전화하여 암호 4849384를 입력하십시오. 웹캐스트의 녹화는 통화 후 약 30일 동안 이용 가능합니다. 참가자들은 시작 15분 전에 접속할 것을 권장합니다.
REGENXBIO Inc. (Nasdaq: RGNX) a annoncé une conférence téléphonique prévue pour jeudi 1er août 2024 à 16h30 ET. Le but de cet appel est de discuter des résultats financiers du deuxième trimestre clos le 30 juin 2024, ainsi que des points marquants opérationnels récents. Les parties intéressées peuvent accéder à l'appel en direct par téléphone ou via webcast sur le site web de REGENXBIO. Pour un accès par téléphone, composez le (646) 307-1963 (national) ou le (800) 715-9871 (international) avec le code d'accès 4849384. Le webcast enregistré sera disponible pendant environ 30 jours après l'appel. Il est conseillé aux participants de se connecter 15 minutes avant l'heure de début.
REGENXBIO Inc. (Nasdaq: RGNX) hat eine Telefonkonferenz für Donnerstag, den 1. August 2024, um 16:30 Uhr ET angekündigt. Zweck des Anrufs ist es, die finanziellen Ergebnisse des zweiten Quartals, das am 30. Juni 2024 endete, sowie die aktuellen betrieblichen Highlights zu besprechen. Interessierte Parteien können den Live-Anruf telefonisch oder über das Webcast auf der Website von REGENXBIO erreichen. Für den telefonischen Zugang wähle (646) 307-1963 (national) oder (800) 715-9871 (international) mit dem Zugangscode 4849384. Der aufgezeichnete Webcast wird voraussichtlich etwa 30 Tage nach dem Anruf verfügbar sein. Teilnehmer werden gebeten, 15 Minuten vor dem Beginn in die Konferenz einzutreten.
- None.
- None.
To access the live call by phone, dial (646) 307-1963 (domestic) or (800) 715-9871 (international) and enter the passcode 4849384. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call. Those who plan on participating are advised to join 15 minutes prior to the start time.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-august-1-to-discuss-second-quarter-2024-financial-results-and-recent-operational-highlights-302206370.html
SOURCE REGENXBIO Inc.
FAQ
When is REGENXBIO (RGNX) hosting its Q2 2024 earnings call?
How can investors access REGENXBIO's (RGNX) Q2 2024 earnings call?
What period will REGENXBIO's (RGNX) Q2 2024 financial results cover?
How long will the recorded webcast of REGENXBIO's (RGNX) Q2 2024 earnings call be available?
